Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
As obesity remains a critical global health issue, Eli Lilly’s blockbuster drug Zepbound positions the company to potentially become the first trillion-dollar drugmaker, with its market cap already at $858 billion. The strong performance of both Eli Lilly and its competitor Novo Nordisk, whose diabetes and weight loss drugs are driving significant market gains, make these stocks top holdings at our firm. With continued demand and new approvals, especially in China, we remain confident in the future growth and disruptive potential of these companies in the health and diet industry.